High Prevalence of Diabetes to be the Precursor for Growth of Global Oral Proteins and Peptides Market

The International Diabetes Federation states that there will be 592 million diabetics by the end of 2035 up from 382 million in 2013, which has created a significant need for advanced therapies. In addition to this shocking statistic, the growth in the number of cancer cases and other chronic conditions are also in need of improved therapeutics. The global oral proteins and peptides market is thus catering to the vast needs of proteins and peptides that are required for treating various types of medical needs. The natural forms of proteins and peptides present in the body are responsible for regulating and protecting the bodily functions. They play a vital role in transporting oxygen and other substances through the body. Additionally, proteins and peptides also give the body a solid structure.

Research Report:

Q. What are the possible drivers for the global oral proteins and peptides market? 

A. Transparency Market Research observes that increasing investments in research and development activities are expected to drive the growth of the market. The market will also be fueled by remarkable technological advancements, which have resulted in the development protein formulations that can be administered orally without any change in the pharmacokinetic aspects and therapeutic activity. The market is also thriving due to the high prevalence of chronic conditions across the globe.

Q. What are the drugs and technologies available in the global market? 

A. The drugs available in the global oral proteins and peptides market are Plecantide, Linaclotide, Octreolin, IN-105 (inslulin), and Ostora amongst others.  Analysts state that the majority of the molecules are being studied for the management of diabetes. Market research reveals that insulin is most popularly used product amongst all others due to the growing number diabetics around the world. However, pharmaceutical companies are also expected to focus on developing oral proteins and peptides for treating bone diseases and gastric disorders. The key technologies available in this market are Peptelligence, Gastrointestinal Permeation Enhancement Technology (GIPET), Eligen, Multi-Matrix Systems (MMX), and oral antibody platform.

Q. Who are the key players in the global market?

A. The leading players operating in the global oral proteins and peptides market are Pfizer, Inc., Sanofi-Aventis LLC, Roche, Inc., ZydusCadilla Healthcare, Johnson & Johnson, Novartis AG, and Abbott Laboratories amongst others. The growing investment from venture capitalists is yet another reason fuelling the growth of the global market. Product innovation and focus on delivering effective products is expected to be the main strategy for these players in the near future.

Despite the steady market drivers, the global oral proteins and peptides market faces some tough challenges such as high cost of research and development and the significant amount of capital required to set up businesses. Both of these factors has largely dissuaded new entrants from being a part of the market dynamics. However, innovations in the routes of administration of oral proteins and peptides such as inhalation, intranasal, and transdermal have opened up several growth opportunities for the global players in recent years.


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports